Nigeria Atrial Fibrillation Registry

NCT05936164 | Not Yet Recruiting

• 1 other identifier: NigAfibRegistry_V.2
• Study Type: observational
• Target: 4,000
• Locations: 0 countries
• Sites: N/A

Brief Summary

Atrial fibrillation is the most common sustained cardiac arrhythmia (rhythm abnormality) encountered in clinical practice. It contributes significantly to the risk of cardiac symptoms, hospital admissions, cardiovascular related morbidity and mortality and increased healthcare cost. AF has significant impact on healthcare cost. The major drivers of the cost are hospitalisations, stroke and loss of productivity. Globally AF accounts for less than 1% of all deaths. However, because it co-exists with other conditions, it contributes to worse prognosis compared to persons who do not have AF. New onset AF in HF patients may be associated with particularly poor prognosis. Most of the published data and current knowledge on AF epidemiology are based on studies in Europe and North America. The information obtainable from previous studies in sub-Saharan Africa is limited. Many of the studies were retrospective. There is also paucity of information on burden of AF (both in hospital and community), clinical profile and outcome of AF in Nigeria in particular and Africa in general. The primary objective of this study is to determine the clinical characteristics, outcome as well as cost genetic features of AF in Nigeria. The project will provide information on: i. Hospital and community burden of AF in Nigeria; ii. Clinical features, mode of presentation and risk factors for AF; iii. Provide data on AF related outcomes as well as prognostic factors.

Conditions

Atrial Fibrillation

Keywords

Atrial fibrillation, arrhythmias, heart failure

Outcome Measures

Primary Outcomes (1)

• All cause mortality

  All deaths

  12 months

Secondary Outcomes (3)

• Hospitalisation

  At 12 months

• Stroke

  12 months

• Any other thromboembolic events

  12 months

Eligibility Criteria

• Age: 15 Years - 100 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Subjects are eligible to participate if they are 15 years and above and have 12-lead ECG features of atrial fibrillation

You may qualify if:

• All cases of confirmed atrial fibrillation

You may not qualify if:

• Refusal of consent

Sponsors & Collaborators

• University College Hospital, Ibadan: lead

MeSH Terms

Conditions

Atrial Fibrillation; Arrhythmias, Cardiac; Heart Failure

Condition Hierarchy (Ancestors)

Heart Diseases; Cardiovascular Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Year
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: DR

Study Record Dates

• First Submitted: June 29, 2023
• First Posted: July 7, 2023
• Study Start: October 1, 2023
• Primary Completion (Estimated): October 1, 2027
• Study Completion (Estimated): December 31, 2028
• Last Updated: July 7, 2023

Record last verified: 2023-06